<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1233125</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Simultaneous radical cystectomy and nephroureterectomy in the treatment of panurothelial carcinoma: a systematic review and single-arm meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2313252"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Huimin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Zhi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chongjian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Caixia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jiahao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bao</surname>
<given-names>Erhao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2344891"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Xuesong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1436434"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Urology, Affiliated Hospital of North Sichuan Medical College</institution>, <addr-line>Nanchong</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Urology, Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Radiology, Affiliated Hospital of North Sichuan Medical College</institution>, <addr-line>Nanchong</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Clemens Mathias Rosenbaum, Asklepios Hospital Barmbek, Germany</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Simone Morra, University of Naples Federico II, Italy; Francesco Di Bello, University of Naples Federico II, Italy</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Xuesong Yang, <email xlink:href="mailto:xuesongyang2022@163.com">xuesongyang2022@163.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1233125</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>06</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Liu, Zhang, Wen, Jiang, Huang, Wang, Chen, Wang, Bao and Yang</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Liu, Zhang, Wen, Jiang, Huang, Wang, Chen, Wang, Bao and Yang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Panurothelial carcinoma is a rare and aggressive malignancy that requires effective treatment strategies to enhance patient outcomes.</p>
</sec>
<sec>
<title>Methods</title>
<p>We conducted a systematic search of English publications in databases including PubMed, Embase, Cochrane Library, and Web of Science up to May 2023. The quality of the literature was assessed using the Newcastle-Ottawa Scale (NOS) and the Methodological Quality and Synthesis of Case Series and Case Reports tool. Data statistics and analysis were performed using Stata 15.1 software (StataSE, USA).</p>
</sec>
<sec>
<title>Results</title>
<p>Six studies involving 339 patients were included in the analysis. Meta-analysis revealed that Simultaneous Radical Cystectomy and Nephroureterectomy had 2-year and 5-year overall survival rates of 68% (95% CI 60%-76%, I<sup>2</sup> = 12.4%, P &lt; 0.001) and 44% (95% CI 36%-53%, I<sup>2 </sup>= 0, P &lt; 0.001), respectively. The 2-year and 5-year progression-free survival rates were 91% (95% CI 86%-95%, I<sup>2 </sup>= 95%, P &lt; 0.001) and 65% (95% CI 58%-73%, I<sup>2 </sup>= 91.5%, P &lt; 0.001), respectively. The 2-year and 5-year cancer-specific survival rates were 73% (95% CI 66%-81%, I<sup>2 </sup>= 16.7%, P &lt; 0.001) and 57% (95% CI 49%-66%, I<sup>2 </sup>= 0, P &lt; 0.001), respectively. Additionally, the incidence of minor complications was 19% (95% CI 15%-23%, P &lt; 0.01), major complications was 49% (95% CI 34%-63%, P &lt; 0.01), and the intraoperative blood transfusion rate was 53% (95% CI 44%-61%, P &lt; 0.01).</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Simultaneous radical cystectomy and nephroureterectomy represent feasible approaches for the treatment of Panurothelial carcinoma. Nonetheless, a comprehensive assessment of the surgical risks and benefits is imperative, and larger-scale prospective cohort studies are required to validate therapeutic efficacy. </p>
</sec>
<sec>
<title>Systematic review registration</title>
<p>
<uri xlink:href="https://www.crd.york.ac.uk/PROSPERO">https://www.crd.york.ac.uk/PROSPERO</uri>, identifier CRD42023426401.</p>
</sec>
</abstract>
<kwd-group>
<kwd>radical cystectomy</kwd>
<kwd>nephroureterectomy</kwd>
<kwd>panurothelial carcinoma</kwd>
<kwd>UTUC</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
<counts>
<fig-count count="7"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="47"/>
<page-count count="12"/>
<word-count count="3476"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Genitourinary Oncology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Urothelial cell carcinoma (UCC) is emerging as the fourth most prevalent cancer in men, with 90%-95% of cases being bladder urothelial cancer and the majority of the remaining cases being upper tract urothelial carcinoma (UTUC) (<xref ref-type="bibr" rid="B1">1</xref>). The overall incidence rate of UTUC stands at 1.1 cases per 100,000 individuals, with a lower rate of 0.89 cases per 100,000 individuals for advanced-stage UTUC. Notably, in patients with metastatic UTUC, the overall one-year survival rate reaches 60.3% (<xref ref-type="bibr" rid="B2">2</xref>). Panurothelial carcinoma (Panuc) is a rare yet highly invasive malignancy (<xref ref-type="bibr" rid="B3">3</xref>). It represents the simultaneous occurrence of bladder urothelial cancer and UTUC (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>), accounting for approximately 11% of UTUC cases (<xref ref-type="bibr" rid="B6">6</xref>). Radical cystectomy (RC) is the established gold standard surgical procedure for treating invasive bladder urothelial cancer, while radical nephroureterectomy is the preferred treatment for invasive UTUC (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). However, due to the rarity of Panurothelial carcinoma and the lack of original studies, there is currently no consensus on its optimal treatment strategy.</p>
<p>Previous small-scale case studies have reported on simultaneous radical cystectomy and nephroureterectomy (RCUN), suggesting that RCUN may reduce metastasis and disease recurrence. However, the safety and efficacy of RCUN in the treatment of Panuc patients remain unclear due to the limited sample sizes of these studies (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>), Recently, large-scale studies by Subiela et&#xa0;al. (<xref ref-type="bibr" rid="B11">11</xref>) and Britton et&#xa0;al. (<xref ref-type="bibr" rid="B12">12</xref>) have reported on the treatment of Panuc with RCUN. The study by Zein et&#xa0;al. (<xref ref-type="bibr" rid="B13">13</xref>) provided a comprehensive overview of perioperative outcomes in patients undergoing RCUN treatment for Panurothelial carcinoma. However, their included literature comprised numerous case reports and lacked statistical analyses of postoperative tumor survival data.</p>
<p>To better evaluate the effectiveness of RCUN in the treatment of Panuc, we conducted a systematic review and a single-arm meta-analysis. The aim of this study was to provide a comprehensive and scientifically grounded basis for the treatment of Panuc, offering valuable insights for clinical decision-making.</p>
</sec>
<sec id="s2">
<title>Method</title>
<p>We conducted the present meta-analysis in accordance with the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (<xref ref-type="bibr" rid="B14">14</xref>) Furthermore, we have registered the study in PROSPERO (CRD42023426401) to ensure transparency and adherence to best practices in systematic reviews and meta-analyses.</p>
<sec id="s2_1">
<title>Literature search strategy</title>
<p>We conducted a comprehensive search of the Embase, Web of Science, and Cochrane Library databases up until May 2023 to identify studies that met the inclusion criteria. Our search strategy involved combining relevant terms related to the intervention and the patient population: ((Radical Cystectomy OR Radical Cystectomies OR Radical Cystectom*) AND (Nephroureterectomy OR Nephroureterectomies OR Nephroureterectom*) AND (Upper tract urothelial carcinoma OR UTUC OR panurothelial carcinoma OR PanUC)). To ensure the comprehensiveness of our search, we also manually reviewed the references of relevant articles. Only studies reported in English were included.</p>
</sec>
<sec id="s2_2">
<title>Study selection</title>
<p>The inclusion criteria were defined using the PICOS approach. The eligible studies needed to meet the following criteria: (1) patients diagnosed with Panuc, (2) patients who underwent simultaneous treatment with both RC and RCUN, (3) one or more of the following outcomes: perioperative, oncologic, or survival outcomes, and (4) study designs including cohort studies, single-arm studies, or randomized controlled trials (RCTs). Studies were excluded if they met any of the following criteria: (1) unavailable data for analysis, (2) comments, reviews, case reports, abstracts, or editorials, (3) duplicate publications.</p>
</sec>
<sec id="s2_3">
<title>Data collection</title>
<p>The data extraction process was carried out independently by two reviewers. The extracted data included the following information: (1) general information such as the first author, publication year, and country; (2) population characteristics including the number of patients, age, body mass index (BMI), median follow-up time, pathological stage, and outcomes; (3) perioperative outcomes such as operative time, estimated blood loss, transfusion rates, and length of stay; (4) assessment of minor complications (defined as Clavien grade 1-2) and major complications (defined as Clavien grade &#x2265;3); (5) survival data including overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Any discrepancies that arose during the data extraction process were resolved through consensus or consultation with a third reviewer. Only studies reported in English were included in the reference list.</p>
</sec>
<sec id="s2_4">
<title>Bias risk assessment</title>
<p>The quality of the included publications was assessed using the Newcastle-Ottawa Scale (NOS) (<ext-link ext-link-type="uri" xlink:href="https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp">https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp</ext-link>) (<xref ref-type="bibr" rid="B15">15</xref>). The NOS was used to evaluate the case selection, comparability, and outcome reporting of each study. Two authors independently conducted the quality assessment, and any disagreements were resolved through discussion and consensus among all authors. For case series and case reports, the methodological quality and synthesis were evaluated using the &#x201c;Methodological quality and synthesis of case series and case reports&#x201d; tool (<xref ref-type="bibr" rid="B16">16</xref>).</p>
</sec>
<sec id="s2_5">
<title>Statistical analysis</title>
<p>We utilized STATA 15.1 software (StataSE, USA) to perform a meta-analysis combining overall survival (OS), recurrence-free survival (RFS), cancer-specific survival (CSS), and perioperative outcomes in patients who underwent simultaneous radical cystectomy and nephroureterectomy (RCUN) for Panuc. KM curve data was extracted and estimated using Digitizer 4.1 and Adobe Photoshop (<xref ref-type="bibr" rid="B17">17</xref>). All pooled results were presented with 95% confidence intervals (CIs). Inter-study heterogeneity was assessed using the I<sup>2</sup> statistic and the Cochran Q test (<xref ref-type="bibr" rid="B18">18</xref>). For studies with high heterogeneity (I<sup>2</sup> &#x2265; 50%), a random-effects model was employed, while studies with low heterogeneity (I<sup>2</sup> &#x2264; 50%) were analyzed using a fixed-effects model. Statistical significance was considered at a P-value &lt; 0.05. Sensitivity analysis was conducted by excluding each study individually to assess the robustness of our findings. However, due to the limited number of studies (three or fewer), sensitivity analysis could not be performed.As the number of included studies was ten or fewer, the power of the tests for publication bias assessment was inadequate (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Hence, we were unable to conduct a thorough evaluation of publication bias.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Baseline characteristics</title>
<p>A total of 648 studies were retrieved. After initial screening, we identified 7 potentially eligible studies, of which 6 studies met the inclusion criteria and were included in our analysis (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Literature screening flowchart.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g001.tif"/>
</fig>
<p>The included studies originated from the USA, China, and Spain. The sample sizes ranged from 8 to 170 patients, totaling 339 patients who underwent simultaneous radical cystectomy and nephroureterectomy for Panurothelial Carcinoma. Open surgery accounted for 64% of the total cases, while minimally invasive procedures constituted 36% of the total cohort. <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> summarizes the age, BMI, gender, date of follow-up, and other baseline information of the included patients. <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> provides an overview of the tumor stage, history of previous abdominal surgery, history of previous chemotherapy, and other relevant data for the included patients. <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref> presents the quality evaluation of the case series.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Characteristics of studies and patient populations.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Study</th>
<th valign="bottom" align="center">Country</th>
<th valign="bottom" align="center">No.of patient</th>
<th valign="bottom" align="center">Gender(male/femal)</th>
<th valign="bottom" align="center">BMI</th>
<th valign="bottom" align="center">Age(years)</th>
<th valign="bottom" align="center">Charlson comorbidity index</th>
<th valign="bottom" align="center">ASA score</th>
<th valign="bottom" align="center">Median follow-up time</th>
<th valign="bottom" align="center">NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">Barros2008</td>
<td valign="bottom" align="center">USA</td>
<td valign="bottom" align="center">8</td>
<td valign="bottom" align="center">7 \1</td>
<td valign="bottom" align="center">25.8(9.6)</td>
<td valign="bottom" align="center">76.5(65-79)</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">3.25(0.6)</td>
<td valign="bottom" align="center">9(1-45)</td>
<td valign="bottom" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="bottom" align="center">Britton2023</td>
<td valign="bottom" align="center">USA</td>
<td valign="bottom" align="center">39</td>
<td valign="bottom" align="center">32 \7</td>
<td valign="bottom" align="center">28.1(2.8)</td>
<td valign="bottom" align="center">72(65-76))</td>
<td valign="bottom" align="center">1.9(1.1)</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">6.3(1.9-11.1)</td>
<td valign="bottom" align="center">7</td>
</tr>
<tr>
<td valign="bottom" align="center">Carpinito2022</td>
<td valign="bottom" align="center">USA</td>
<td valign="bottom" align="center">27</td>
<td valign="bottom" align="center">22 \5</td>
<td valign="bottom" align="center">28(4.4)</td>
<td valign="bottom" align="center">71(66-75)</td>
<td valign="bottom" align="center">4(3.5-7)</td>
<td valign="bottom" align="center">2.1(0.36)</td>
<td valign="bottom" align="center">36(11-52)</td>
<td valign="bottom" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="bottom" align="center">Kanabur2022</td>
<td valign="bottom" align="center">USA</td>
<td valign="bottom" align="center">190</td>
<td valign="bottom" align="center">145 \45</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">69(55-83)</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="bottom" align="center">Ou2010</td>
<td valign="bottom" align="center">China</td>
<td valign="bottom" align="center">8</td>
<td valign="bottom" align="center">5 \3</td>
<td valign="bottom" align="center">24.6(3.7)</td>
<td valign="bottom" align="center">66.9(6.6)</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">2.8(0.3)</td>
<td valign="bottom" align="center">28.1(2-54)</td>
<td valign="bottom" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="bottom" align="center">Subiela2023</td>
<td valign="bottom" align="center">Spain</td>
<td valign="bottom" align="center">67</td>
<td valign="bottom" align="center">57 \ 10</td>
<td valign="bottom" align="center">26.6(23-29.1)</td>
<td valign="bottom" align="center">64(56-71)</td>
<td valign="bottom" align="center">5(4-5)</td>
<td valign="bottom" align="center">2.8(0.6)</td>
<td valign="bottom" align="center">38(17-88)</td>
<td valign="bottom" align="center">&#x2013;</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Tumor staging and pathological data of patient populations.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Study</th>
<th valign="bottom" align="center">No. of Pelvic Lymph Nodes Dissected, n(%)</th>
<th valign="bottom" align="center">Upper Tract Involvement,n</th>
<th valign="bottom" align="center">Neoadjuvant Chemotherapy</th>
<th valign="bottom" align="center">Previous Surgery,n(%)</th>
<th valign="bottom" align="center">RC<break/>Pathology</th>
<th valign="bottom" align="center">NU Pathology</th>
<th valign="bottom" align="center">operative approach,n</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">Barros2008</td>
<td valign="bottom" align="center">7(87.5%)</td>
<td valign="bottom" align="center">renal pelvis and ureter:(n=2)<break/>ureter:(n=3)<break/>renal pelvis:(n=1)</td>
<td valign="bottom" align="center">75%</td>
<td valign="bottom" align="center">7(87.5%)</td>
<td valign="bottom" align="center">pT1G3:1; pT4G3:1; pT2 G2:3; pT0:1; pT3 G2:1; pTis:1</td>
<td valign="bottom" align="center">Ptis:2; pT0:2; pT1:1;pTa:1; pT2:1; pT3:1</td>
<td valign="bottom" align="center">Laparoscopy(n=7), Robotic(n=1)</td>
</tr>
<tr>
<td valign="bottom" align="center">Britton2023</td>
<td valign="bottom" align="center">31(79)</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">10.30%</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">29 (74.4%)&lt;pT2; 6 (15.4%)pT2; 4 (10.3%)&gt;pT2; 37 (94.9%)N0/X, 2 (5.1%) N+;</td>
<td valign="bottom" align="center">Tis7 (17.5%); Ta12 (30.8%); T0 1 (2.5%); T1 10 (25.0%); T2 8 (20.0%)T3 1 (2.5%);</td>
<td valign="bottom" align="center">Laparoscopy(n=4), Robotic(n=1), Open(n=34)</td>
</tr>
<tr>
<td valign="bottom" align="center">Carpinito2022</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">8 (30%)</td>
<td valign="bottom" align="center">5(18.5%)</td>
<td valign="bottom" align="center">cTa/Tis 13 (48%)<break/>cT1 4 (15%)<break/>cT2 + 10 (37%)</td>
<td valign="bottom" align="center">cTa/Tis 11 (41%)<break/>cT1 1 (3.7%)<break/>cT2 + 1 (3.7%)</td>
<td valign="bottom" align="center">Laparoscopy(n=9), Robotic(n=5), Open(n=13)</td>
</tr>
<tr>
<td valign="bottom" align="center">Kanabur2022</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">Open(n=125), Laparoscopy(n=65)</td>
</tr>
<tr>
<td valign="bottom" align="center">Ou2010</td>
<td valign="bottom" align="center">8(100)</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">NA</td>
<td valign="bottom" align="center">T1, high 3; T1, low 1; CIS, high 1; CIS, low1</td>
<td valign="bottom" align="center">T1 3; Ta 2; T2a 1;</td>
<td valign="bottom" align="left">Robotic(n=8)</td>
</tr>
<tr>
<td valign="bottom" align="center">Subiela2023</td>
<td valign="bottom" align="center">67(100)</td>
<td valign="bottom" align="center">Renal pelvis 23 (34.3%)<break/>Proximal ureter 13 (19.4%)<break/>Distal ureter 27 (49.3%)<break/>Pelvis and ureter 4 (6%)</td>
<td valign="bottom" align="center">33 (49.3%)</td>
<td valign="bottom" align="center">19(28.4%)</td>
<td valign="bottom" align="center">G1/G2 37 (55.3)<break/>G3 30 (44.7)</td>
<td valign="bottom" align="center">NMI disease (Tis, Ta, T1) 41 (61.2%); T2 6 (8%); T3-T4 20 (29.8%)</td>
<td valign="bottom" align="center">Open(n=45), Laparoscopy(n=22)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>NA, Not Available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Quality assessment of case series.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Description</th>
<th valign="bottom" align="center">Selection</th>
<th valign="bottom" align="center">Ascertainment</th>
<th valign="bottom" align="center"/>
<th valign="bottom" align="center">Causality</th>
<th valign="bottom" align="center"/>
<th valign="bottom" align="center"/>
<th valign="bottom" align="center"/>
<th valign="bottom" align="center">Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center">1. Does the patient(s)<break/>represent(s) the whole<break/>experience of the investigator<break/>(centre) or is the selection<break/>method unclear to the extent<break/>that other patients with similar<break/>presentation may not have been<break/>reported</td>
<td valign="bottom" align="center">2. Was the<break/>exposure<break/>adequately<break/>ascertained?</td>
<td valign="bottom" align="center">3. Was the<break/>outcome<break/>adequately ascertained?</td>
<td valign="bottom" align="center">4. Were other<break/>alternative causes that<break/>may explain the<break/>observation ruled out?</td>
<td valign="bottom" align="center">5. Was there a<break/>challenge/rechallenge<break/>phenomenon?</td>
<td valign="bottom" align="center">6. Was<break/>there a<break/>dose&#x2013;<break/>response<break/>effect?</td>
<td valign="bottom" align="center">7. Was<break/>follow-up<break/>long enough<break/>for<break/>outcomes to<break/>occur?</td>
<td valign="bottom" align="center">8. Is the case(s) described<break/>with sufficient details to<break/>allow other investigators<break/>to replicate the research<break/>or to a llow practitioners<break/>make inferences related<break/>to their own practice?</td>
</tr>
<tr>
<td valign="bottom" align="center">Barros2008</td>
<td valign="bottom" align="center">U</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">N</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
</tr>
<tr>
<td valign="bottom" align="center">Carpinito2022</td>
<td valign="bottom" align="center">U</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">N</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
</tr>
<tr>
<td valign="bottom" align="center">Ou2010</td>
<td valign="bottom" align="center">U</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">N</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
</tr>
<tr>
<td valign="bottom" align="center">Subiela2023</td>
<td valign="bottom" align="center">U</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">N</td>
<td valign="bottom" align="center">Y</td>
<td valign="bottom" align="center">Y</td>
</tr>
<tr>
<td valign="bottom" align="center">Y, yes; U, unclear; N, no.</td>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
<td valign="bottom" align="center"/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_2">
<title>Outcome analysis</title>
<sec id="s3_2_1">
<title>Perioperative outcomes</title>
<p>The results of the single-arm meta-analysis showed that the operative time for simultaneous radical cystectomy and nephroureterectomy was 378.34 minutes (95% CI 368.95, 387.74, P &lt; 0.001) (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>), the length of hospital stay was 8.04 days (95% CI 7.77, 8.31) (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>), and the blood loss was 711.36 ml (95% CI 638.85, 783.87, P &lt; 0.001) (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>). Additionally, the incidence of postoperative minor complications (Clavien grade 1-2) was 19% (95% CI 15%-23%) (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>), the incidence of postoperative major complications (Clavien grade &#x2265; 3) was 49% (95% CI 34%-63%) (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>), and the intraoperative blood transfusion rate was 53% (95% CI 44%-61%) (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>). The median survival time was 42.21 months (95% CI 38.18, 46.23) (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>), and the tumor metastasis rate was 34% (95% CI 26%, 42%) (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Forest plots of Perioperative outcome: <bold>(A)</bold> operation time was 378.34 minutes (95% CI 368.95, 387.74); <bold>(B)</bold> length of hospital stay was 8.04 days (95% CI 7.77, 8.31); <bold>(C)</bold> blood loss was 711.36 ml (95% CI 638.85, 783.87).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Forest plots of Perioperative outcome: <bold>(A)</bold> minor complications rate was 19% (95% CI 15%, 23%); <bold>(B)</bold> major complications rate was 49% (95% CI 34%, 63%); <bold>(C)</bold> blood transfusion rate was 53% (95% CI 44%, 61%).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g003.tif"/>
</fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Forest plot<bold>s</bold> of Oncologic Outcomes: <bold>(A)</bold> median survival time was 42.21 months (95% CI 38.18, 46.23); <bold>(B)</bold> tumor metastasis rate was 34% (95% CI 26%, 42%).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g004.tif"/>
</fig>
</sec>
<sec id="s3_2_2">
<title>Survival outcome</title>
<sec id="s3_2_2_1">
<title>Overall survival</title>
<p>Three studies (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>) reported two-year and five-year overall survival rates after RCUN. Meta-analysis demonstrated that the overall survival rate was 68% (95% CI 60%, 76%, I<sup>2</sup> = 12.4%, P &lt; 0.001) at 2 years (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>), and 44% (95% CI 36%, 53%, I<sup>2</sup> = 0, P &lt; 0.001) at 5 years at 5 years (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Forest plots of overall survival: <bold>(A)</bold> two years survival rate was 68% (95% CI 60%, 76%); <bold>(B)</bold> five years survival rate was 44% (95% CI 36%, 53%).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g005.tif"/>
</fig>
</sec>
<sec id="s3_2_2_2">
<title>Recurrence-free survival</title>
<p>Three studies (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>) reported two-year and five-year recurrence-free survival rates after RCUN. Meta-analysis showed that the recurrence-free survival rate was 91% (95% CI 86%, 95%, I<sup>2</sup> = 95%, P &lt; 0.001) at 2 years (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>), and 65% (95% CI 58%, 73%, I<sup>2</sup> = 91.5%, P &lt; 0.001) at 5 years (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Funnel plot of recurrence-free survival: <bold>(A)</bold> two years survival rate was 91% (95% CI 86%, 95%); <bold>(B)</bold> five years survival rate was 65% (95% CI 58%, 73%).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g006.tif"/>
</fig>
</sec>
<sec id="s3_2_2_3">
<title>Cancer-specific survival</title>
<p>Three studies (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>) reported two-year and five-year cancer-specific survival rates after RCUN. Meta-analysis revealed that the cancer-specific survival rate was 73% (95% CI 66%, 81%, I<sup>2 </sup>= 16.7%, P &lt; 0.001) at 2 years (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>), and 57%(95%CI 49%, 66%, I<sup>2 </sup>= 0, P&lt;0.001) at 5 years (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Funnel plot of cancer-specific survival: <bold>(A)</bold> two years survival rate was 73% (95% CI 66%, 81%); <bold>(B)</bold> five years survival rate was 57%(95%CI 49%, 66%).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1233125-g007.tif"/>
</fig>
</sec>
</sec>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>This study represents a systematic review and single-arm meta-analysis investigating the efficacy of simultaneous radical cystectomy and nephroureterectomy (RCUN) in the treatment of Panuc. By conducting a comprehensive evaluation of the relevant literature, we have derived several important conclusions.</p>
<p>First and foremost, our research findings have revealed a disheartening efficacy of RCUN in the treatment of Panuc. Meta-analysis demonstrates a remarkable two-year recurrence-free survival rate exceeding 90%. This outcome can possibly be attributed to the effective eradication of all tumor lesions through simultaneous resection of the bladder and renal ureter, consequently reducing the risks of residual lesions and metastasis. However, the two-year overall survival rate and cancer-specific survival rate both fail to surpass 75%, suggesting that the surgical outcomes may not have met the expected efficacy. It is noteworthy that previous studies have reported a 4-6% urethral recurrence rate in patients undergoing RC (<xref ref-type="bibr" rid="B4">4</xref>), and tumor size can nearly directly predict the staging and grading of UTUC (<xref ref-type="bibr" rid="B23">23</xref>). Populations from different regions and residing environments may exhibit varying cancer-specific mortality risks in UTUC (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Furthermore, tumor liver metastasis independently predicts poorer survival rates (<xref ref-type="bibr" rid="B26">26</xref>).Risk factors such as smoking, a history of upper tract urothelial carcinoma (UTUC), and chronic kidney disease have also been suggested as potential explanations for malignancy recurrence (<xref ref-type="bibr" rid="B27">27</xref>&#x2013;<xref ref-type="bibr" rid="B30">30</xref>). Nonetheless, our survival results indicate that Panuc exhibits a more aggressive behavior compared to primary epithelial UC. Therefore, we propose that RCUN may represent a viable treatment option, particularly for high-risk patients and complex cases involving panurothelial carcinoma.</p>
<p>Secondly, our study also observed a higher risk of surgical complexity and postoperative complications associated with RCUN. This outcome is anticipated as simultaneous excision increases the surgical difficulty and trauma (<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>), potentially resulting in longer operative times and an increased incidence of postoperative complications. Patients diagnosed with preoperative uremia exhibit an elevated risk of intraoperative immune system dysfunction, cardiovascular complications, and anesthesia-related adverse events. Perioperative complications, including bleeding, infection, atelectasis, and cardiovascular or cerebrovascular events, are more likely to occur (<xref ref-type="bibr" rid="B34">34</xref>&#x2013;<xref ref-type="bibr" rid="B36">36</xref>). Hence, multidisciplinary collaboration involving anesthesiology, critical care medicine, nephrology, and urology is indispensable for the management of such patients. Consequently, when considering the feasibility of simultaneous surgery, physicians need to carefully evaluate the potential benefits against the surgical risks and the patient&#x2019;s postoperative rehabilitation requirements. Cutaneous ureterostomy(CU) stands out as a crucial approach for managing early complications, offering advantages such as shorter urinary diversion surgical times, reduced blood loss, lower transfusion rates, and shorter hospital stays (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). When compared to patients undergoing ileal conduit diversion, it may also exhibit a potentially lower occurrence of intraoperative and postoperative complications (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Current experience with robot-assisted radical cystectomy (RC) patients suggests that there appears to be no significant difference in the incidence of complications between intracorporeal and extracorporeal ileal conduit diversion (<xref ref-type="bibr" rid="B41">41</xref>). Given the diverse surgical approaches included in the studies, there is presently an insufficient quantity of data to adequately compare open and minimally invasive treatments for RCUN. However, in the context of radical cystectomy, minimally invasive procedures appear to exhibit a lower transfusion rate in comparison to open surgery (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). Whether this outcome is applicable to RCUN remains subject to verification in subsequent research.</p>
<p>Moreover, given the high risk of recurrent residual urothelium in Panuc (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>), regular postoperative testing for residual urothelium should be performed in patients, and prophylactic urethrectomy should even be considered. These findings underscore the importance of meticulous urinary tract management during the perioperative and follow-up periods. Early and long-term follow-up is crucial to timely detect any recurrence. During the perioperative period, patients should receive specialized care and monitoring to ensure proper wound healing. Additionally, appropriate rehabilitation measures, including physical therapy and rehabilitation training, should be implemented to facilitate the recovery of urinary function. These measures should be widely implemented and optimized to provide better treatment options and enhance both survival and quality of life for patients with panurothelial carcinoma.</p>
<p>Furthermore, we recommend comparing our results with alternative treatment modalities such as radiation therapy, chemotherapy, or immunotherapy. Such comparisons will help determine the status and comparative advantages of RCUN in the treatment of panurothelial carcinoma. Unfortunately, the reduced kidney function observed in all RCUN patients in our study makes subsequent treatments, such as chemotherapy, virtually impossible (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). Moreover, integrating study findings with clinical practice guidelines can assist clinicians in formulating more specific treatment plans and decisions tailored to individual patient management.</p>
<p>Finally, we strongly encourage further collaborative and multicenter studies to validate our findings. Multicenter studies can increase sample sizes, enhance the statistical power of the research, and improve the reliability and external validity of the results. Additionally, international collaborative studies can facilitate comparisons between patient populations from diverse regions and ethnicities, enabling a deeper understanding of the effects of RCUN in different demographic groups.</p>
<p>Regarding future research directions, we propose further investigation into the optimal criteria for patient selection in RCUN. While our current study included a diverse range of patients, including high-risk individuals and complex cases, the assessment of feasibility in other patient subgroups was limited. Therefore, future studies should focus on evaluating the efficacy and safety of this surgical approach in specific patient subsets.</p>
<p>Furthermore, an important area of research lies in the technical refinement of simultaneous surgery. The introduction of novel surgical techniques and instruments holds promise for enhancing surgical precision and safety. For instance, the utilization of robot-assisted surgery and microscopy can improve procedural accuracy, visualization, and minimize damage to normal tissue. Comparative studies exploring the effectiveness of different techniques and instruments in simultaneous surgery should be conducted to optimize surgical outcomes (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>It is important to acknowledge the limitations of our study. The inclusion of a limited number of studies, along with the partial absence of research data and the potential for selection and publication biases, may have influenced our results. Furthermore, our study is based on retrospective data analysis, which only provides a lower level of evidence. It is crucial to carefully weigh the potential benefits against the surgical risks and prioritize postoperative urinary tract management. Future investigations should focus on refining patient selection criteria, technical advancements, and obtaining higher levels of evidence.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusions</title>
<p>Panurothelial carcinoma represents a rare and highly invasive malignancy. Given the substantial postoperative complications associated with the RCUN approach, a meticulous evaluation of the surgical risks and benefits becomes imperative. Further research and collaborative efforts are warranted to validate our findings, enhance therapeutic strategies, and ultimately ameliorate the prognosis of patients afflicted by upper urinary tract urothelial carcinoma.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>YL: Protocol development, data collection and management, data analysis and manuscript writing. HZ: Protocol development, data collection and management, data analysis and manuscript writing. XY: Protocol development, data collection and management, data analysis and manuscript writing. ZW: Protocol development, data management, data analysis and manuscript writing. YJ: Data management, data analysis and manuscript writing. JH: Data management, data analysis and manuscript writing. CC: Data management and manuscript writing. CW: Data management and manuscript writing. JW: Data management and manuscript writing. EB: Data management and manuscript writing. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank the researchers and study participants for their contributions. Thanks to Ms. Yu Jiang for her encouragement and support to YL in his medical career.</p>
</ack>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Fuchs</surname> <given-names>HE</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Cancer statistics, 2021</article-title>. <source>CA Cancer J Clin</source> (<year>2021</year>) <volume>71</volume>(<issue>1</issue>):<fpage>7</fpage>&#x2013;<lpage>33</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21654</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colla Ruvolo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Nocera</surname> <given-names>L</given-names>
</name>
<name>
<surname>Stolzenbach</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Wenzel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cucchiara</surname> <given-names>V</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma</article-title>. <source>Eur Urol Oncol</source> (<year>2021</year>) <volume>4</volume>(<issue>5</issue>):<fpage>792</fpage>&#x2013;<lpage>801</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.euo.2020.11.005</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Singla</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Characteristics and treatment outcomes of pan-urothelial cell carcinom a: a descriptive analysis of 45 patients</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<elocation-id>18014</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep18014</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gakis</surname> <given-names>G</given-names>
</name>
<name>
<surname>Black</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Bochner</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Boorjian</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Stenzl</surname> <given-names>A</given-names>
</name>
<name>
<surname>Thalmann</surname> <given-names>GN</given-names>
</name>
<etal/>
</person-group>. <article-title>Systematic review on the fate of the remnant urothelium after radical cystectomy</article-title>. <source>Eur Urol</source> (<year>2017</year>) <volume>71</volume>(<issue>4</issue>):<page-range>545&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eururo.2016.09.035</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Assel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Benfante</surname> <given-names>N</given-names>
</name>
<name>
<surname>Pietzak</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bagrodia</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cha</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical Outcomes in Patients with Panurothelial Carcinoma Treated wit h Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence</article-title>. <source>J Urol</source> (<year>2017</year>) <volume>198</volume>(<issue>3</issue>):<page-range>546&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.juro.2017.03.120</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cosentino</surname> <given-names>M</given-names>
</name>
<name>
<surname>Palou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gaya</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Breda</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rodriguez-Faba</surname> <given-names>O</given-names>
</name>
<name>
<surname>Villavicencio-Mavrich</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Upper urinary tract urothelial cell carcinoma: location as a predictiv e factor for concomitant bladder carcinoma</article-title>. <source>World J Urol</source> (<year>2013</year>) <volume>31</volume>(<issue>1</issue>):<page-range>141&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00345-012-0877-2</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roupr&#xea;t</surname> <given-names>M</given-names>
</name>
<name>
<surname>Babjuk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Burger</surname> <given-names>M</given-names>
</name>
<name>
<surname>Capoun</surname> <given-names>O</given-names>
</name>
<name>
<surname>Cohen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Comp&#xe9;rat</surname> <given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>European association of urology guidelines on upper urinary tract urot helial carcinoma: 2020 update</article-title>. <source>Eur Urol</source> (<year>2021</year>) <volume>79</volume>(<issue>1</issue>):<fpage>62</fpage>&#x2013;<lpage>79</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eururo.2020.05.042</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Bochner</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Chou</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dreicer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kamat</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Lerner</surname> <given-names>SP</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/A STRO/SUO guideline</article-title>. <source>J Urol</source> (<year>2017</year>) <volume>198</volume>(<issue>3</issue>):<page-range>552&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.juro.2017.04.086</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barros</surname> <given-names>R</given-names>
</name>
<name>
<surname>Frota</surname> <given-names>R</given-names>
</name>
<name>
<surname>Stein</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Turna</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gill</surname> <given-names>IS</given-names>
</name>
<name>
<surname>Desai</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>Simultaneous laparoscopic nephroureterectomy and cystectomy: a preliminary report</article-title>. <source>Int Braz J urol</source> (<year>2008</year>) <volume>34</volume>(<issue>4</issue>):<page-range>413&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/s1677-55382008000400003</pub-id>. discussion 421.</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ou</surname> <given-names>YC</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Hemal</surname> <given-names>AK</given-names>
</name>
</person-group>. <article-title>Simultaneous robot-assisted nephroureterectomy and cystectomy in patients with uremia and multifocal urothelial carcinoma</article-title>. <source>J endourol</source> (<year>2011</year>) <volume>25</volume>(<issue>6</issue>):<page-range>979&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/end.2010.0602</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subiela</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez-Padilla</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Huguet</surname> <given-names>J</given-names>
</name>
<name>
<surname>Aumatell</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rodr&#xed;guez-Faba</surname> <given-names>O</given-names>
</name>
<name>
<surname>Krajewski</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Oncological and renal function outcomes in patients who underwent simultaneous radical cystectomy and nephroureterectomy for synchronous or metachronous panurothelial carcinoma</article-title>. <source>Urology</source> (<year>2023</year>) <volume>172</volume>:<page-range>157&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urology.2022.08.064</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Britton</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Gottlich</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Tarrell</surname> <given-names>RF</given-names>
</name>
<name>
<surname>Thapa</surname> <given-names>P</given-names>
</name>
<name>
<surname>Joyce</surname> <given-names>DD</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>PH</given-names>
</name>
<etal/>
</person-group>. <article-title>Perioperative and oncologic outcomes associated with simultaneous radical cystectomy and nephroureterectomy</article-title>. <source>Urology</source> (<year>2023</year>) <volume>172</volume>:<page-range>149&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urology.2022.09.039</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zein</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nasrallah</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Abou Heidar</surname> <given-names>NF</given-names>
</name>
<name>
<surname>Najdi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hneiny</surname> <given-names>L</given-names>
</name>
<name>
<surname>El Hajj</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Concurrent radical cystectomy and nephroureterectomy indications and outcomes: a systematic review and comparative analysis</article-title>. <source>Ther Adv Urol</source> (<year>2023</year>) <volume>15</volume>:<elocation-id>17562872231171757</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/17562872231171757</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shamseer</surname> <given-names>L</given-names>
</name>
<name>
<surname>Moher</surname> <given-names>D</given-names>
</name>
<name>
<surname>Clarke</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ghersi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liberati</surname> <given-names>A</given-names>
</name>
<name>
<surname>Petticrew</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Preferred reporting items for systematic review and meta-analysis prot ocols (PRISMA-P) 2015: elaboration and explanation</article-title>. <source>BMJ</source> (<year>2015</year>) <volume>350</volume>:<elocation-id>g7647</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.g7647</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stang</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment o f the quality of nonrandomized studies in meta-analyses</article-title>. <source>Eur J Epidemiol</source> (<year>2010</year>) <volume>25</volume>(<issue>9</issue>):<page-range>603&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10654-010-9491-z</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murad</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Sultan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Haffar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bazerbachi</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Methodological quality and synthesis of case series and case reports</article-title>. <source>BMJ Evidence-Based Med</source> (<year>2018</year>) <volume>23</volume>(<issue>2</issue>):<page-range>60&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmjebm-2017-110853</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tierney</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Stewart</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Ghersi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Burdett</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sydes</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Practical methods for incorporating summary time-to-event data into me ta-analysis</article-title>. <source>Trials</source> (<year>2007</year>) <volume>8</volume>:<elocation-id>16</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1745-6215-8-16</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higgins</surname> <given-names>JPT</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Deeks</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Altman</surname> <given-names>DG</given-names>
</name>
</person-group>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source> (<year>2003</year>) <volume>327</volume>(<issue>7414</issue>):<page-range>557&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sterne</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Gavaghan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Egger</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Publication and related bias in meta-analysis: power of statistical te sts and prevalence in the literature</article-title>. <source>J Clin Epidemiol</source> (<year>2000</year>) <volume>53</volume>(<issue>11</issue>):<page-range>1119&#x2013;29</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0895-4356(00)00242-0</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ioannidis</surname> <given-names>JPA</given-names>
</name>
<name>
<surname>Terrin</surname> <given-names>N</given-names>
</name>
<name>
<surname>Schmid</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Olkin</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>The case of the misleading funnel plot</article-title>. <source>BMJ</source> (<year>2006</year>) <volume>333</volume>(<issue>7568</issue>):<fpage>597</fpage>&#x2013;<lpage>600</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.333.7568.597</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carpinito</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Cook</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Tverye</surname> <given-names>AN</given-names>
</name>
<name>
<surname>Gold</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Lotan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Margulis</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: A single-institution series</article-title>. <source>Can Urol Assoc J = J l&#x2019;Association Des urologues du Canada.</source> (<year>2022</year>) <volume>16</volume>(<issue>7</issue>):<fpage>E363</fpage>&#x2013;<lpage>e369</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.5489/cuaj.7612</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanabur</surname> <given-names>P</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Godoy</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Perioperative outcomes of patients undergoing concurrent nephroureterectomy and cystectomy for urothelial cancer: an nsqip database analysis</article-title>. <source>J Urol</source> (<year>2022</year>) <volume>207</volume>(<issue>5</issue>):<page-range>E978&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1097/JU.0000000000002639.15</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colla Ruvolo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Nocera</surname> <given-names>L</given-names>
</name>
<name>
<surname>Stolzenbach</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Wenzel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Califano</surname> <given-names>G</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor size predicts muscle-invasive and non-organ-confined disease in upper tract urothelial carcinoma at radical nephroureterectomy</article-title>. <source>Eur Urol focus</source> (<year>2022</year>) <volume>8</volume>(<issue>2</issue>):<fpage>498</fpage>&#x2013;<lpage>505</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.euf.2021.03.003</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colla Ruvolo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Stolzenbach</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Nocera</surname> <given-names>L</given-names>
</name>
<name>
<surname>Deuker</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wenzel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Higher cancer mortality in rural upper urinary tract urothelial carcinoma patients</article-title>. <source>Urol internationalis</source> (<year>2021</year>) <volume>105</volume>(<issue>7-8</issue>):<page-range>624&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000513361</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coll&#xe0; Ruvolo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wenzel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nocera</surname> <given-names>L</given-names>
</name>
<name>
<surname>W&#xfc;rnschimmel</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Shariat</surname> <given-names>SF</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of race on stage at presentation and survival in upper tract urothelial carcinoma</article-title>. <source>Urol Oncol</source> (<year>2021</year>) <volume>39</volume>(<issue>11</issue>):<fpage>788.e7</fpage>&#x2013;<lpage>788.e13</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urolonc.2021.07.001</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colla Ruvolo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Deuker</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wenzel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nocera</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wurnschimmel</surname> <given-names>C</given-names>
</name>
<name>
<surname>Califano</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma</article-title>. <source>Urol Oncol</source> (<year>2022</year>) <volume>40</volume>(<issue>9</issue>):<page-range>411 e1&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urolonc.2022.06.009</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fahmy</surname> <given-names>O</given-names>
</name>
<name>
<surname>Khairul-Asri</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Schubert</surname> <given-names>T</given-names>
</name>
<name>
<surname>Renninger</surname> <given-names>M</given-names>
</name>
<name>
<surname>K&#xfc;bler</surname> <given-names>H</given-names>
</name>
<name>
<surname>Stenzl</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis</article-title>. <source>Urol Oncol</source> (<year>2018</year>) <volume>36</volume>(<issue>2</issue>):<page-range>54&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urolonc.2017.11.007</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanna</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zganjar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lyon</surname> <given-names>T</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tollefson</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Karnes</surname> <given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>A contemporary analysis of urethral recurrence following radical cystectomy</article-title>. <source>J urol</source> (<year>2021</year>) <volume>206</volume>(<issue>4</issue>):<page-range>970&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/ju.0000000000001842</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boorjian</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Weight</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Cheville</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Thapa</surname> <given-names>P</given-names>
</name>
<name>
<surname>Frank</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Risk factors and outcomes of urethral recurrence following radical cystectomy</article-title>. <source>Eur urol</source> (<year>2011</year>) <volume>60</volume>(<issue>6</issue>):<page-range>1266&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eururo.2011.08.030</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huguet</surname> <given-names>J</given-names>
</name>
<name>
<surname>Monllau</surname> <given-names>V</given-names>
</name>
<name>
<surname>Sabat&#xe9;</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rodriguez-Faba</surname> <given-names>O</given-names>
</name>
<name>
<surname>Algaba</surname> <given-names>F</given-names>
</name>
<name>
<surname>Palou</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients</article-title>. <source>Eur Urol</source> (<year>2008</year>) <volume>53</volume>(<issue>4</issue>):<page-range>785&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eururo.2007.06.045</pub-id>. discussion 792-3.</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quek</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Stein</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Daneshmand</surname> <given-names>S</given-names>
</name>
<name>
<surname>Miranda</surname> <given-names>G</given-names>
</name>
<name>
<surname>Thangathurai</surname> <given-names>D</given-names>
</name>
<name>
<surname>Roffey</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>A critical analysis of perioperative mortality from radical cystectomy</article-title>. <source>J Urol</source> (<year>2006</year>) <volume>175</volume>(<issue>3 Pt 1</issue>):<page-range>886&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0022-5347(05)00421-0</pub-id>. discussion 889-90.</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novara</surname> <given-names>G</given-names>
</name>
<name>
<surname>Catto</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>T</given-names>
</name>
<name>
<surname>Annerstedt</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>K</given-names>
</name>
<name>
<surname>Murphy</surname> <given-names>DG</given-names>
</name>
<etal/>
</person-group>. <article-title>Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy</article-title>. <source>Eur urol</source> (<year>2015</year>) <volume>67</volume>(<issue>3</issue>):<fpage>376</fpage>&#x2013;<lpage>401</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eururo.2014.12.007</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bream</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Maurice</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Altschuler</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Abouassaly</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Increased use of cystectomy in patients 75 and older: A contemporary analysis of survival and perioperative outcomes from the national cancer database</article-title>. <source>Urology</source> (<year>2017</year>) <volume>100</volume>:<page-range>72&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urology.2016.08.054</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Chiang</surname> <given-names>PH</given-names>
</name>
</person-group>. <article-title>Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up</article-title>. <source>Japan J Clin Oncol</source> (<year>2010</year>) <volume>40</volume>(<issue>3</issue>):<page-range>241&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jjco/hyp143</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Shee</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Ho</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>CS</given-names>
</name>
</person-group>. <article-title>Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma</article-title>. <source>J urol</source> (<year>2004</year>) <volume>171</volume>(<issue>1</issue>):<page-range>126&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.ju.0000101758.41635.28</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tai</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Chueh</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>HJ</given-names>
</name>
</person-group>. <article-title>Intermediate-term oncological outcomes of hand-assisted laparoscopic versus open bilateral nephroureterectomy for dialysis and kidney transplant patients with upper urinary tract urothelial carcinoma</article-title>. <source>J endourol</source> (<year>2009</year>) <volume>23</volume>(<issue>7</issue>):<page-range>1139&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/end.2008.0162</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deliveliotis</surname> <given-names>C</given-names>
</name>
<name>
<surname>Papatsoris</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chrisofos</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dellis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Liakouras</surname> <given-names>C</given-names>
</name>
<name>
<surname>Skolarikos</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit</article-title>? <source>Urology</source> (<year>2005</year>) <volume>66</volume>(<issue>2</issue>):<fpage>299</fpage>&#x2013;<lpage>304</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urology.2005.03.031</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korkes</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fernandes</surname> <given-names>E</given-names>
</name>
<name>
<surname>Gushiken</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Glina</surname> <given-names>FPA</given-names>
</name>
<name>
<surname>Baccaglini</surname> <given-names>W</given-names>
</name>
<name>
<surname>Tim&#xf3;teo</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review</article-title>. <source>Int Braz J urol: Off J Braz Soc Urol</source> (<year>2022</year>) <volume>48</volume>(<issue>1</issue>):<fpage>18</fpage>&#x2013;<lpage>30</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/s1677-5538.Ibju.2020.0892</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arman</surname> <given-names>T</given-names>
</name>
<name>
<surname>Mher</surname> <given-names>B</given-names>
</name>
<name>
<surname>Varujan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sergey</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ashot</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Health-related quality of life in patients undergoing radical cystectomy with modified single stoma cutaneous ureterostomy, bilateral cutaneous ureterostomy and ileal conduit</article-title>. <source>Int Urol nephrol</source> (<year>2020</year>) <volume>52</volume>(<issue>9</issue>):<page-range>1683&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11255-020-02470-6</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname> <given-names>N</given-names>
</name>
<name>
<surname>Imbimbo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fusco</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ficarra</surname> <given-names>V</given-names>
</name>
<name>
<surname>Mangiapia</surname> <given-names>F</given-names>
</name>
<name>
<surname>Di Lorenzo</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy</article-title>. <source>BJU Int</source> (<year>2016</year>) <volume>118</volume>(<issue>4</issue>):<page-range>521&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bju.13462</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mistretta</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Musi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Colla Ruvolo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Conti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Luzzago</surname> <given-names>S</given-names>
</name>
<name>
<surname>Catellani</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Robot-assisted radical cystectomy for nonmetastatic urothelial carcinoma of urinary bladder: A comparison between intracorporeal versus extracorporeal orthotopic ileal neobladder</article-title>. <source>J endourol</source> (<year>2021</year>) <volume>35</volume>(<issue>2</issue>):<page-range>151&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/end.2020.0622</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mastroianni</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ferriero</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tuderti</surname> <given-names>G</given-names>
</name>
<name>
<surname>Anceschi</surname> <given-names>U</given-names>
</name>
<name>
<surname>Bove</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Brassetti</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Open radical cystectomy versus robot-assisted radical cystectomy with intracorporeal urinary diversion: early outcomes of a single-center randomized controlled trial</article-title>. <source>J urol</source> (<year>2022</year>) <volume>207</volume>(<issue>5</issue>):<page-range>982&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/ju.0000000000002422</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontanet</surname> <given-names>S</given-names>
</name>
<name>
<surname>Basile</surname> <given-names>G</given-names>
</name>
<name>
<surname>Baboudjian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gallioli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Huguet</surname> <given-names>J</given-names>
</name>
<name>
<surname>Territo</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Robot-assisted vs. open radical cystectomy: systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Actas urologicas espanolas</source> (<year>2023</year>) <volume>47</volume>(<issue>5</issue>):<page-range>261&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.acuroe.2023.01.003</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodr&#xed;guez Faba</surname> <given-names>O</given-names>
</name>
<name>
<surname>Palou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Breda</surname> <given-names>A</given-names>
</name>
<name>
<surname>Maroto</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez G&#xf3;mez</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma</article-title>. <source>Urol internationalis</source> (<year>2014</year>) <volume>92</volume>(<issue>2</issue>):<page-range>169&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000353652</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vejlgaard</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maibom</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Stroomberg</surname> <given-names>HV</given-names>
</name>
<name>
<surname>Poulsen</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Thind</surname> <given-names>PO</given-names>
</name>
<name>
<surname>R&#xf8;der</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term renal function following radical cystectomy for bladder cancer</article-title>. <source>Urology</source> (<year>2022</year>) <volume>160</volume>:<page-range>147&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.urology.2021.11.015</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mikhail</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sarcona</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mekhail</surname> <given-names>M</given-names>
</name>
<name>
<surname>Richstone</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Urologic robotic surgery</article-title>. <source>Surg Clinics North America</source> (<year>2020</year>) <volume>100</volume>(<issue>2</issue>):<page-range>361&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.suc.2019.12.003</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mottrie</surname> <given-names>A</given-names>
</name>
<name>
<surname>Larcher</surname> <given-names>A</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>The past, the present, and the future of robotic urology: robot-assisted surgery and human-assisted robots</article-title>. <source>Eur Urol focus</source> (<year>2018</year>) <volume>4</volume>(<issue>5</issue>):<page-range>629&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.euf.2018.10.002</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>